How does Lynparza (olaparib) treat ovarian cancer?
Lynparza is a PARP inhibitor. It works by blocking PARP enzymes that cancer cells use to repair DNA damage. When PARP is blocked, damaged DNA in rapidly dividing tumor cells becomes harder to repair, which can lead to cancer-cell death. This effect is especially strong in tumors that already have defects in DNA repair pathways, such as cancers with BRCA mutations. [1][2]
Why is it especially effective for BRCA-mutated ovarian tumors?
Many ovarian cancers rely on PARP-mediated repair when BRCA1/BRCA2 (key homologous recombination repair genes) are not functioning properly. In BRCA-mutated settings, PARP inhibition creates a form of “synthetic lethality,” where the tumor cannot survive the added DNA repair failure. [1][2]
When is Lynparza used in ovarian cancer (and how does that affect what it’s doing)?
Lynparza can be used in ovarian cancer based on the stage/setting and whether the tumor has certain DNA repair features (for example, BRCA mutation status). In practice, the goal in many uses is to keep tumor growth under control by continuing PARP inhibition after initial treatment or during disease management, rather than giving only short bursts of therapy. [1][2]
What happens to cancer cells at the DNA-repair level?
PARP proteins normally help detect and repair single-strand DNA breaks. Blocking PARP pushes unrepaired damage to collapse replication forks and create double-strand breaks. If a tumor cannot effectively repair double-strand breaks through homologous recombination (as in BRCA-defective cancers), those breaks can drive cell death. [1][2]
What do patients typically mean by “how it works” in day-to-day terms?
Patients usually experience Lynparza as an anticancer pill taken on a schedule. Mechanistically, it targets DNA repair in tumor cells. Clinically, it’s meant to reduce the chance of progression or recurrence in eligible ovarian cancer patients, depending on the treatment line and molecular characteristics. [1][2]
Sources
[1] DrugPatentWatch.com - Lynparza (olaparib) resource: https://www.drugpatentwatch.com/
[2] DrugPatentWatch.com - PARP inhibitors and Lynparza-related information (site references): https://www.drugpatentwatch.com/